Population pharmacokinetics of tanezumab in phase 3 clinical trials for osteoarthritis pain
Open Access
- 15 February 2016
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 81 (4) , 688-699
Abstract
Aims: The aims were to 1) develop the pharmacokinetics model to describe and predict observed tanezumab concentrations over time, 2) test possible covariate parameter relationships that could influence clearance and distribution and 3) assess the impact of fixed dosingvs. a dosing regimen adjusted by body weight.Methods: Individual concentration–time data were determined from 1608 patients in four phase 3 studies conducted to assess efficacy and safety of intravenous tanezumab. Patients received two or three intravenous doses (2.5, 5 or 10 mg) every 8 weeks. Blood samples for assessment of tanezumab PK were collected at baseline, 1 h post‐dose and at weeks 4, 8, 16 and 24 (or early termination) in all studies. Blood samples were collected at week 32 in two studies. Plasma samples were analyzed using a sensitive, specific, validated enzyme‐linked immunosorbent assay.Results: A two compartment model with parallel linear and non‐linear elimination processes adequately described the data. Population estimates for clearance (CL), central volume (V1), peripheral volume (V2), inter‐compartmental clearance, maximum elimination capacity (VM) and concentration at half‐maximum elimination capacity were 0.135 l day–1, 2.71 l, 1.98 l, 0.371 l day–1, 8.03 μg day–1and 27.7 ng ml–1, respectively. Inter‐individual variability (IIV) was included on CL,V1,V2and VM. A mixture model accounted for the distribution of residual error. While gender, dose and creatinine clearance were significant covariates, only body weight as a covariate of CL,V1andV2significantly reduced IIV.Conclusions: The small increase in variability associated with fixed dosing is consistent with other monoclonal antibodies and does not change risk : benefit.Keywords
This publication has 41 references indexed in Scilit:
- Multivalent immune complexes divert FcRn to lysosomes by exclusion from recycling sorting tubulesMolecular Biology of the Cell, 2013
- Dynamics of target-mediated drug disposition: characteristic profiles and parameter identificationJournal of Pharmacokinetics and Pharmacodynamics, 2012
- Antagonism of Nerve Growth Factor-TrkA Signaling and the Relief of PainAnesthesiology, 2011
- Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects ModelsThe AAPS Journal, 2011
- Selection between Michaelis–Menten and target-mediated drug disposition pharmacokinetic modelsJournal of Pharmacokinetics and Pharmacodynamics, 2009
- Population pharmacokinetic analysis of infliximab in patients with ulcerative colitisEuropean Journal of Clinical Pharmacology, 2009
- Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti‐NGF monoclonal antibody, using a repertoire of biosensorsProtein Science, 2008
- Podocytes use FcRn to clear IgG from the glomerular basement membraneProceedings of the National Academy of Sciences, 2008
- A mechanism‐based binding model for the population pharmacokinetics and pharmacodynamics of omalizumabBritish Journal of Clinical Pharmacology, 2007
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976